'mRNA Vaccines Are Extraordinary, but Novavax Is Even Better'
June 25, 2021  13:49
image
At the end of January, reports that yet another COVID-19 vaccine had succeeded in its clinical trials -- this one offering about 70 percent protection -- were front-page news in the United States, and occasioned push alerts on millions of phones. 

But when the Maryland-based biotech firm Novavax announced its latest stunning trial results last week, and an efficacy rate of more than 90 percent even against coronavirus variants, the response from the same media outlets was muted in comparison. 

The difference, of course, was the timing: With three vaccines already authorized for emergency use by the U.S. Food and Drug Administration, the nation is "awash in other shots' already, as the The New York Times put it. Read more
« Back to LIVE

TOP STORIES